18,482 Charles River Laboratories International, Inc. $CRL Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 150.7% during the third quarter, Holdings Channel reports. The institutional investor owned 30,746 shares of the medical research company’s stock after buying an additional 18,482 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $9,070,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in CRL. Tred Avon Family Wealth LLC acquired a new position in shares of Charles River Laboratories International during the third quarter valued at $241,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Charles River Laboratories International by 3,726.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 66,994 shares of the medical research company’s stock valued at $19,764,000 after acquiring an additional 65,243 shares during the last quarter. IFP Advisors Inc boosted its holdings in Charles River Laboratories International by 182.8% in the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 106 shares during the last quarter. TD Waterhouse Canada Inc. increased its position in Charles River Laboratories International by 81,468.9% in the third quarter. TD Waterhouse Canada Inc. now owns 36,706 shares of the medical research company’s stock worth $10,829,000 after purchasing an additional 36,661 shares during the period. Finally, Pension & Wealth Management Advisors Inc. acquired a new stake in Charles River Laboratories International in the third quarter worth about $151,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the subject of several recent research reports. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their target price for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research note on Monday, July 20th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research report on Monday, August 10th. Finally, Jefferies Financial Group boosted their price target on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $302.33.

Insider Buying and Selling

In related news, Director James Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at $9,478,800. This trade represents a 51.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 91,971 shares of company stock worth $26,033,968 over the last quarter. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 1.2%

NYSE CRL opened at $340.64 on Friday. The stock has a 50-day simple moving average of $293.05 and a 200 day simple moving average of $232.43. The company has a market capitalization of $16.26 billion, a PE ratio of -70.24, a P/E/G ratio of 3.22 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 12 month low of $146.20 and a 12 month high of $351.21.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the prior year, the firm posted $3.12 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts forecast that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.